The present invention relates to novel pharmaceutical compositions of Regadenoson and its pharmaceutically acceptable salts, solvates or hydrates in the form of solution, wherein the compositions are free from phosphate buffer and EDTA. Further the invention relates to pharmaceutical composition of Regadenoson comprising a tonicity modifier.